First class in M.Sc Chemistry/Biochemistry or B.Tech in Biological Sciences, or B.Pharm or M.Pharm with valid GATE, UGC/CSIR NET- LS, GPAT Rank or Score. IIT Indore
B.S. 4 years programme / BPharm / MBBS / Integrated BS- MS / MSc / BE / BTech or equivalent degree, with 55% marks and passing of NET / GATE test in any branches of Life Sciences
Application are invited for Training Programme on Pharmacovigilance for NABH Accredited Hospitals at Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, J&K on 23rd October 2026
Completion of designated projects and tasks supporting European Market RA and International Market RA, according to internal Work Instructions, with guidance and direction by the manager and more senior colleagues.
Sun Pharma is India’s No. 1 pharmaceutical company and a leading global player in specialty medicines. With over 40 manufacturing facilities and a diverse portfolio, we deliver high-quality medicines across 100 countries
B. Pharm M. Pharm M.Sc. Chemistry. Chromatographic analysis (HPLC) with Empower 3 software & LI MS Awareness
CMP documentation & data integrity, HPLC Testing of raw materials, in-process & finished products
Testing & Method Validations; Culture Handling, Water & Bioburden Testing; Raw Material and BET Testing Water, Finished and Stability samples, Autoclave, Sterility Testing & observation of canisters.
To support and execute Analytical Method Validation activities, ensure data integrity and regulatory compliance for API products at our Udaipur API Plant.
MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA.
B.Pharma + M.Pharma , M.Sc. / Master’s degree in Pure or Applied Sciences, including Biochemistry, Biotechnology, Microbiology, Nursing, and other relevant Life Sciences disciplines, MBBS degree or a Doctorate in Pure or Applied Sciences.
MSD announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS).
Postgraduate degree in Public Health (MPH)/Epidemiology/ Statistics/Environmental Sciences/Population Sciences/Demography/Health Economics/HTA/Pharmacy (M.Pharm) with 3 years of post PG experience in research/projects and at least one research paper in SCIE journal. AIIMS Mangalagiri
M.Sc. in Chemistry / Chemical Sciences/Pharmaceutical Chemistry/Pharmaceutical Sciences and qualified CSIR-UGC/ICAR/ICMR NET incl. lectureship / assistant professorship or GATE. CDRI October Interview 2026